Lundbeck hit hard by DAYBREAK disaster

25 October 2018
lundbeck-location-big

Thursday was a dark day for Danish CNS specialist Lundbeck (LUND: CO).

Nearly 27% was wiped off the market value of the company after it reported that DAYBREAK, the first Phase III study for Lu AF35700, an investigational once-daily, oral antipsychotic for treatment-resistant schizophrenia (TRS), failed to meet the primary endpoint of statistical superiority versus the current therapy.

"We will continue to advance our pipeline of innovative therapies"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical